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Abstract 
 
During the last decade, gene expression microarrays and array-based 
comparative genomic hybridization (array-CGH) have unraveled the complexity 
of human tumor genomes more precisely and comprehensively than ever before. 
More recently, the simultaneous assessment of global changes in mRNA 
expression and in DNA copy number through “integrative oncogenomic” analyses 
has allowed researchers the access to results uncovered through the analysis of 
one-dimensional datasets, thus accelarating cancer gene discovery. In this 
chapter, we discuss the major contributions of DNA microarrays to the study of 
hematological malignancies, focusing on the integrative oncogenomic 
approaches that correlate genomic and transcriptomic data. We also present the 
basic aspects of these methodologies and their present and future application in 
clinical oncology. 
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1. INTRODUCTION.  
 
The application of gene expression microarrays has allowed the definition of 
common patterns of gene expression that can distinguish pathologically different 
tumors, but has also revealed degrees of heterogeneity between and within 
tumors.1-5 Alizadeh and colleagues were the first to use microarrays to identify 
subtypes of a single disease (diffuse large B cell lymphoma) that could only be 
defined by their gene expression patterns.6 Since this pioneering report, gene 
expression profiling has made significant contributions in basic and applied 
cancer research by providing useful prognostic biomarkers, defining novel 
oncogenic pathways, characterizing molecular portraits of transformation and 
metastasis, and revealing unique gene signatures of therapeutic response.5,7-9 
Today, the extrapolation of some of these microarray findings to more efficient 
and cost-effective laboratory techniques, such as quantitative PCR, flow 
cytometry or immunohistochemistry, are remarkable examples that place basic 
science closer to clinical medicine.8 A different DNA microarray technology, 
termed comparative genomic hybridization (CGH) to microarrays (from now on, 
array-CGH), can detect and map changes in the DNA copy number that are 
present in tumors but not in the corresponding non-tumoral germline 
sequences.10-12 In seminal papers, Pinkel, Lichter and colleagues used high-
resolution array-CGH with bacterial artificial chromosomes (BACs) as clones to 
precisely define amplicon structures and deletion borders in tumors, mapping the 
corresponding gene loci targeted by the amplification and deletion processes.12-14 
Since then, notable improvements in the resolution and sensitivity of current 
genome-wide array-CGH platforms have made possible the accurate screenning 
for genome-wide aberrations in large tumor sets.11,15,16 More recent 
oligonucleotide-based single nucleotide polymorphism (SNP) microarrays were 
able to detect not only DNA copy number changes but also copy-neutral genetic 
aberrations such as loss of heterozygosity caused by uniparental disomy.17 
Overall, systematic scanning of cancer genomes using array-CGH has served to 
describe patterns of genetic alterations linked to the genesis and dissemination 
of human tumors.   
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Yet gene expression microarrays and array-CGH are both mature technologies, 
the simultaneous assessment of global changes in mRNA expression and in 
DNA profile through “integrative oncogenomics” represents a relatively novel 
approach that attempts to accelarate cancer genome annotation and gene target 
discovery at a genome scale.5,18 Using these comparative systems, which need 
support from robust bioinformatic tools, researchers are having access to results 
uncovered through the analysis of one-dimensional datasets.Notable examples 
are the identification of specific chemotherapy response signatures by microarray 
analyses of multiple human biopsies and human-like tumors from genetically 
manipulated mice, or the construction of regulatory genetic networks where 
participating cancer genes can be functionally characterized in proper molecular 
and cellular contexts.18 In this chapter, we discuss the major contributions of  
DNA microarrays to the study of hematological malignancies, focusing on the 
integrative oncogenomic approaches that correlate genomic and transcriptomic 
data. We also present the basic aspects of these methodologies and their 
application in clinical oncology. 
 
2. APPLICATION OF GENE EXPRESSION MICROARRAYS IN 
HEMATOLOGICAL TUMORS 
 
The study of hematological malignancies has particularly benefited from gene 
expression analysis, and crucial discoveries about diagnosis, prognosis and 
pathogenetic mechanisms of these diseases have been made. In acute myeloid 
leukemia (AML), good prognostic subgroups are defined by the presence of 
specific chromosomal rearrangements such as the translocations t(8;21) and 
t(15;17) or the inversion of chromosome 16, whereas translocations afecting the 
MLL gene in chromosome 11q23 or deletions of chromosome 5q or 7q 
characterize poor prognostic subgroups.19,20 Gene expression profiling has been 
able to identify these leukemia subgroups with high accuracy. In two landmark 
papers, gene expression profiling detected not only previously defined genetically 
and prognostically subgroups in AML but also novel clusters with adverse 
prognosis.21,22 A different approach evaluated the expression profiling of CD34+ 
hematopoietic stem/progenitor cells, revealing distinct subtypes of therapy-
related AML.23 In B-cell acute lymphoblastic leukemia (B-ALL), gene expression 
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profiles distinguished each of the prognostically important leukemia subtypes, 
including those with specific chromosomal translocations: t(1;19)-E2A-PBX1, 
t(9;22)-BCR-ABL, t(11q23)-MLL and t(12;21)-TEL-AML1, as well as those with 
hyperdiploidy with >50 chromosomes. Further, within some of these genetic 
subgroups, those patients who eventually relapsed presented typical gene 
expression patterns that allowed their recognition.24 Gene expression studies 
have also deciphered novel oncogenic pathways in childhood T-cell acute 
lymphoblastic leukemia (T-ALL),25 and in adult T-cell lymphoma in leukemic 
phase.26 Notably, these studies identified T-ALL subgroups with molecular 
signatures associated with favorable prognosis (HOX11), while those expressing 
TAL1, LYL1 or HOX11L2 presented much worse responses to treatment.25 A 
common aspect of these studies is the identification of molecular subgroups 
defined by oncogenes that are aberrantly expressed in the absence of 
chromosomal abnormalities. Therefore, gene expression microarrays can identify 
all leukemias within identical molecular subgroups, including cases with typical 
chromosomal rearrangements but also others that would be missed by standard 
cytogenetic and molecular techniques. One additional goal of gene expression 
microarrays has been to search for therapeutic targets in patients with leukemia. 
FLT3 mutations, a common genetic abnorality in AML, is an independent 
prognostic indicator of poor outcome and response to standard chemotherapy.27 
In a cDNA microarray study of childhood leukemias, FLT3 was found to be 
overexpressed in patients carrying MLL gene translocations. Subsequent studies 
showed that FLT3 inhibitors are active against leukemias with MLL 
rearangements in vitro and in vivo.28,29 In conclusion, it is unquestionable that 
gene expression arrays have had an enormous impact in our current 
understanding of acute leukemias. To move on, clinical trials should evaluate 
novel therapies in patients who are stratified according to the molecular profiles 
determined at the time of diagnosis.  
 
Molecular profiling has also been crucial in deciphering the pathogenesis of B-
cell malignancies. Diffuse large B cell lymphoma (DLBCL) can be divided into 
molecular subgroups based on their cellular origins that significantly differed in  
therapy response and cure rate.6,30 Importantly, these molecular subsets of 
disease, namely germinal center DLBCL (GC-DLBCL) and activated B-cell 
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DLBCL (ABC-DLBCL), were only distinguishable by gene expression profililng 
and not by other current diagnostic methods.6 Following these studies, 
immunohistochemistry-based assays were developed to classify ABC-DLBCL 
and GC-DLBCL cases on a routine basis.31 Additionally, the lymphochip survival-
prediction data were further validated through measuring single expression of six 
genes (LMO2, BCL6, FN1, CCND2, SCYA3, and BCL2) by quantitative PCR, 
which was sufficient to predict overall survival in patients with DLBCL treated 
either with CHOP or more recently, with CHOP plus the anti-CD20 monoclonal 
antibody rituximab (R-CHOP).32,33 Most importantly, translation of this molecular 
knowledge to the clinic may lead to therapeutic tailoring in patients with DLCBL. 
For instance, ABC-DLBCL cases show constitutive activation of NF-kB genes 
and thus respond uniquely to NF-kB inhibitors.34 Further refinement of these 
investigations showed a cooperative signaling through the STAT3 and NF-kB 
pathways in a subset of ABC-DLBCL cases. A small-molecule inhibitor of JAK 
signaling, which blocked STAT3 signature expression, was toxic only for ABC-
DLBCL lines and synergized with an NF-kB inhibitor.35  
 
Additional Affymetrix microchips ptofiled molecular signatures of DLBCL cases 
with different responses to standard chemotherapy, thus revealing unique 
pathways associated with poor responses.36 Moreover, the use of multitple 
clustering and gene set enrichment analysis allowed the identification of three 
discrete subsets of DLBCL termed "oxidative phosphorylation," "B-cell 
receptor/proliferation," and "host response" (HR), pointing out that the tumor 
microenvironment and the host inflammatory response are defining features in 
DLBCL.37 These molecular routes altered in subsets of patients with DLBCL may 
represent important targets for therapeutic intervention using specific drugs,37-40 
some of which are being used in phase II clinical trials.41,42 Subsequent studies 
have revealed a transcriptional signature with differential expression of BCL6 
target genes that can accurately identify DLBCL cases carrying genetic 
alterations of the BCL6 oncogene. Notably, the DLBCL subgroup with the BCL6 
expression signature is uniquely sensitive to BCL6 inhibitors.43-45  
  
Other remarkable achievements of gene expression analysis of B-cell 
malignancies include the recognition of molecular links between apparently 
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different entities such as Hodgkin disese and primary mediastinal B-cell 
lymphoma, suggesting a putative common cellular origin;46-48 the discovery of 
better prognostic markers, such as ZAP70 expression measurement as an 
indicator of survival length of patients with B-cell chronic lymphocytic leukemia 
(B-CLL);49-52 a more accurate molecular definition of Burkitt lymphoma that 
expands the spectrum of the WHO criteria for this disease;53,54 the correlation of 
survival duration in patients with follicular lymphoma with gene expression 
profiles reflecting an interaction between tumor cells and infiltrating immune 
cells;55,56 the understanding of the roles of cell cycle control and DNA repair 
pathways that correlate with cell proliferation and clinical outcome in mantle cell 
lymphoma;57,58 the definition of a typical gene expression profiling of hairy cell 
leukemia that reveals a phenotype related to memory B cells with altered 
expression of chemokine and adhesion receptors;59 and the investigation of the 
multistep transformation of monoclonal gammopathy of undetermined 
significance to multiple myeloma by global gene expression analysis.60-63 
 
Recently, expression microarrays have been used to investigate questions on 
leukemia biology and therapy in more complex functional model systems. 
Krivtsov and colleagues demonstrated in a mouse model of leukemia initiated by 
MLL-AF9 oncogenic fusion that leukemia stem cells maintain the global identity 
of the progenitor cells from which they arosed while activating a limited stem-cell 
or self-renewal-associated gene expression program characteristic of 
hematopoietic stem cells.64 In a different report, Ngo and colleagues used a 
doxycycline-inducible retroviral vector for the expression of small hairpin RNAs 
(shRNAs) for 2,500 human genes in ABC-DLBCL and GC-DLBCL cell lines. 
Each vector was engineered to contain a unique 60-base-pair 'bar code', allowing 
the abundance of an individual shRNA vector within a population of transduced 
cells to be measured using microarrays of the bar-code sequences. Results 
determined that a subset of shRNA vectors was depleted from the transduced 
cells when shRNA expression was induced, uncovering CARD11 gene as a key 
component responsible for the constitutive NF-kB activation in ABC-DLBCL but 
not in GC-DLBCL.65 Further validating the screening, this group of investigators 
found mutations in exons encoding the coiled-coil domain of CARD11 gene that 
activated NF-kB pathway in 9,6% of patients with ABC-DLBCL.66 These data 
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point out CARD11 as an atractive therapeutic target in this lymphoma subgroup, 
but we still do not know the genetic lessions in the remaining 90% of ABC-
DLBCL cases with NF-kB signaling. Similar massive genomic screenings using 
RNAi have been recently applied to other tumor cell types, providing alternative 
functional information of cancer cells.67-69 Palomero and colleagues applied gene 
expression microarrays to T-ALL cell lines that were classified as sensitive or 
resistant to gamma-secretase inhibitors, which block a proteolytic cleavage 
required for NOTCH1 activation. Among the genes targets that were found 
differentially expressed was the tumor suppressor PTEN. Further investigations 
demonstrated that NOTCH1 regulates the expression of PTEN and the activity of 
the phosphoinositol-3 kinase (PI3K)-AKT signaling pathway in normal and 
leukemic T cells.70 This novel observation suggests the need to simultaneously 
inhibit both pathways to improve therapeutic efficacy in T-ALL. 
 
Microarray technologies have been also used to measure global expression of a 
class of small non-coding RNA species, known as microRNAs in tumors.71,72 One 
of the cancers where miRNA profiling has provided critical information is B-CLL. 
Patients with B-CLL and prolongued survival were characterized by down-
regulation of miR-15a and miR-16-1 located at 13q14.3.73,74 On the other hand, 
B-CLL cases with unmutated IgVH or with elevated expression of ZAP70 showed 
high levels of TCL1 due to low-level expression of miR-29 and miR-181, which 
directly target this oncogene.75 These data suggest that B-CLL is a disease in 
which the main pathogenetic alterations may occur in miRNAs.  
 
3. DNA COPY NUMBER VARIATION IN LEUKEMIA, LYMPHOMA AND 
MYELOMA 
 
Tumor genomes usually show a large diversity of abnormalities, ranging from 
point mutations to overt chromosomal aberrations, that have been accumulated 
through the process of malignant transformation. Albeit array-CGH cannot detect 
small sequence mutations or reciprocal chromosomal translocations, this 
technology has facilitated the description of global portraits of DNA copy number 
aberrations in tumors with high precision and resolution.76 In hematologic 
malignancies, array-CGH has led to the identification of known amplicons as well 
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as hidden gene amplifications unappreciated by other genetic screens, such as 
those containing c-MYC in 8q24 in DLBCL and follicular lymphoma, REL ad 
BCL11A genes in DLBCL, JAK2 and PDL2 in primary mediastinal B cell 
lymphoma, BMI1 in mantle cell lymphoma, and CCND3 and BYSL in DLBCL.47,77-
80
 Some of these aberrations showed unexpected patterns of complexity only 
discovered through array-CGH studies. For instance, a detailed mapping of the 
18q21.3 amplicon disclosed two major target sites involving BCL2 and MALT1 
genes in follicular lymphoma and MALT lymphoma, respectively.81 A number of 
the amplicon targets included genes commonly involved in IG-related 
chromosomal translocations.82 Moreover, some of these genomic amplifications 
seem to originate after regional chromosomal translocations. For example, 
chromosome 8q24 sequences surrounding c-MYC loci are frequently amplified in 
many B-cell malignancies carrying a previous t(8;14)(q24;q32).79,83 This is also 
the case for the lymphomas develped in deficient mice for P53 and 
nonhomologous end-joining (NHEJ) genes, that present complex genomic 
rearrengements with coamplification of c-MYC (chromosome 15) and IgH 
(chromosome 12) sequences.84 Whether these secondary genomic 
amplifications have any biological impact or merely reflects local genomic 
instability remains unknown. Overall, genomic amplification functions as a 
mechanism of oncogene activation alternative to IG-related translocations in B-
cell lymphoma (Figure 1A). In one interesting study, amplification of 7p22 in adult 
T-cell leukemia/lymphoma pinpointed CARD11 as the possible target, a gene 
that has been recently implicated as a NF-kB activator in ABC-DLBCL.66,85 
However, its implication in T-cell leukemia/lymphoma, which also shows 
constitutive NF-kB activation, awaits further studies. Non-coding microRNAs may 
also be te target of genomic amplification. In the chromosome 13q31.3 
amplificon, commonly observed in follicular lymphoma, GC-DLBCL, mantle cell 
lymphoma and splenic marginal zone lymphoma, the miR-17-92 cluster results in 
overexpression of up to 500 fold (Figure 1B). These microRNAs positively target 
c-MYC oncogene in B-cell lymphomas,86,87 and have been implicated in several 
biological processes depending on the cellular context, such as the control of 
monocytopoiesis through AML1 targeting and M-CSF receptor upregulation,88 or 
the promotion of proliferation and the inhibition of differentiation of lung epithelial 
progenitor cells.89 In three recent studies, the miR-17-92 cluster has been shown 
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to have critical roles in normal B-cell lymphopoiesis as well as in the 
pathogenesis of B-cell lymphomas and some autoinmune disorders in mice.90-92 
 
Figure 1. A) Array CGH representation showing genomic amplification of 6p21.2 (left) leading to overexpression of PIM1 
oncogene in mantle cell lymphoma (right). B) High-level amplification of 13q31.3 targeting the miR-17-92 cluster in 
Karpas 1718 cell line (left). Using quantiative PCR, overexpression of the 7 miRs in the cluster is demostrated in 
comparisson to normal marginal zone-derived IgM+IgD+CD27+ B cells (right). C) Homozygous deletion of INK4c/P18 
gene in mantle cell lymphoma detected by array CGH (upper left). The genomic loss is associated with low expression 
at the RNA level (shown in gene expression microarrays, upper right) and at the protein level (shown by 
immunohistochemistry (bottom). 
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Localization and rapid delineation of areas of genomic loss has been one of the 
major achievemnts of the application of array-CGH in tumors. Initial reports 
mapped deletions of known tumor suppressor genes such as P53, P16, ARF and 
FHIT that resulted inactivated with variable frequencies in many cancer types.93-
99
 Similar studies have also discovered the loci of novel genes inactivated in B-
cell malignancies, such as the pro-apoptotic BIM in chromosome 2q13 that is 
disrupted by minimal bi-allelic deletions in mantle cell lymphoma; the PRMD1 
gene in chromosome 6q21, frequently targeted by deletion of one allele and by 
truncatig mutation of the remaining allele in ABC-DLBCL but not in GC-DLBCL;  
the NF-kB inactivator gene TNFAIP3, which shows bi-allelic deletion in ocular 
MALT lymphoma, follicular lymphoma and DLBCL, and the INK4c/P18 gene 
targeted by bi-allelic deletion or heterozygous loss and mutation of the remaining 
allele in mantle cell lymphoma (Figure 1C).100-108 The use of DNA microarrays 
containing 32,000 overlapping BACs has enhanced the detection sensitivity of 
array-CGH devices, for instance by mapping intra immunoglobulin gene deletions 
at 2p11 and 22q11 chromosomes as small as 130 kb.109 Positional identification 
of suppressor genes in genomic deletions has also been investigated by array-
CGH in mouse models of cancer. A pioneering report by Hodgson and 
colleagues used array-CGH to scan the genomes of mouse islet carcinomas, 
revealing regional alterations that are syntenic to human genome sequences 
containing candidate oncogenes and suppressor genes.110 In a different study, 
Mao and colleagues studied radiation-induced lymphomas from P53 deficient 
mice. Lymphomas from P53+/- mice, but not those from P53-/- mice, showed 
frequent loss of heterozygosity and a 10% mutation rate of FBXW7/hCDC4, a 
gene encoding a ubiquitin ligase implicated in the control of chromosome 
stability. Further investigations showed that FBXW7+/- mice have greater 
susceptibility to radiation-induced tumorigenesis, but most tumours retain and 
express the wild-type allele, indicating that FBXW7 is a haploinsufficient tumour 
suppressor gene.111 However, interpretation of these microarray approaches in 
mouse models of cancer may be difficult, because BAC array-CGH studies of 
normal genomes from different strains of common laboratory mice revealed 
important segmental and sequence variations.112 
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Genome-wide approaches using Affymetrix SNP-CGH technology have recently 
demonstrated their power of high-resolution to identify new molecular lesions in 
different cancer types. These sudies revealed deletion, amplification, intragenic 
mutation and structural rearrangement in genes encoding principal regulators of 
B lymphocyte development and differentiation in 40% of B-ALL cases, 
preferentially targeting the PAX5 gene.113 In accordance with these unexpected 
data, Cobaleda and colleagues reported that mice lacking PAX5 in mature B 
cells developed aggressive B-cell malignancies, which were identified by their 
gene expression profile as progenitor cell tumours.114 In addition, CCAAT 
enhancer-binding protein (CEBP) transcription factors CEBPA and CEBPB, 
which down-regulate PAX5 in B-cells,115 have been shown to be over-expressed 
in B-ALL through IG-related translocation.116 Collectively, these findings suggest 
that block of genes controlling B-cell development and differentiation, especially 
of PAX5 either by genetic inactivation or by functional suppresion through CEBP 
family members, contributes to B-cell ALL pathogenesis.  
 
Efforts are being made to translate the correlation of genomic and clinical data 
detected by DNA microarrays into more feasible and applicable clinical tests. B-
CLL can be considered as a prototype disease where length of patient survival 
can be predicted by the presence of chromosomal aberrations associated with 
poor prognosis (deletions of chromosomes 11q22-q23 and 17p13) or with 
favorable prognosis (deletion of 13q14 or cases with normal karyotype).117 
Routine detection of these genetic alterations is currently performed by FISH 
technique of bone marow or peripheral blood samples obtained at diagnosis in 
many laboratories throughout the world.118 An automated BAC array-CGH 
detected with high precission all these changes in a series of 106 patients with B-
CLL, especially in those with >50% of tumoral cells in blood or marrow 
samples.119 Mantle cell lymphoma (MCL) is also characterized by a set of 
genomic aberrations that target genes involved in the pathogenesis of the 
disease. Examples include the genomic amplification of chromosomes 8q24 
affecting c-MYC, 10p13 involving BMI1 oncogene and 11q13 targeting 
CCND1/cyclin D1, and the losses of 8p21.3 including TRAIL-R1/R2 genes, 9p21 
(INK4A/ARF), 11q23 (ATM) and 17p13.1 (P53).83,120,121 The pattern of these 
alterations has been correlated with tumor phenotypes and thus, blastoid variants 
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of MCL usually display inactivation of P16/INK4A and P53 genes whereas 
indolent forms of MCL, usually having mutated IgVH genes, frequently show 
deletion of chromosome 8p.83,120,121 Although most patients with MCL show poor 
clinical outcome with current immunochemotherapy regimens, the long-term 
survivors can be identified by a characteristic genomic profile defined by the 
absence of deletions of P53, P16/ARF and chromosome 9q21-q22, and by the 
presence of the deletion of chromosome 1p21-p22.83,122 In both B-CLL and MCL, 
the development of disease-specific CGH microchips may be of value in the 
clinic, as should allow testing the genomic profiles as prognostic and predictive 
factors of response to novel therapies. In a recent report, high-density SNP-CGH 
arrays were used to analyze genome-wide changes of copy number and allele 
status in B-CLL samples from patients that were sensitive or resistant to MDM2 
inhibitors. These studies conclusively demonstrate that P53 status is the major 
determinant of response to MDM2 inhibitors in B-CLL.123 In a study of 107 
follicular lymphoma (FCL) diagnostic biopsies with an array CGH platform 
containing over 26,819 BAC clones covering >95% of the human genome,  68 
regional alterations were identified in >10% of cases. Importantly, 11 of these 
areas were independent predictors of overall survival using a multivariate 
analysis that included IPI score. Further, two of the 11 regions (deletions of 1p36 
and 6q21-q24) were also predictors of transformation risk (Cheung et al, in 
press). These genetic data may be useful to identify FCL high-risk patients as 
candidates for risk-adapted therapies.    
 
The acquisition of uniparental disomy (UPD) is a common event in cancer. 
Genome-wide SNP analysis has revealed large-scale cryptic regions of UPD in 
many hematologic tumors. In AML, this alerations are non-random and contain 
homozygous mutations in genes known to be mutational targets in leukemia 
(WT1, FLT3, CEBPA, and RUNX1).124,125 A high proportion of patients with 
myeloproliferative disorders, including polycythemia vera, essential 
thrombocythemia and chronic idiopathic myelofibrosis, carry a dominant gain-of-
function mutation of JAK2.126-128 Using SNP-CGH, the UPD of chromosome 9p 
typical of these entities has provided the molecular mechanism of homozygos 
mutation of JAK2 in these entities.129 These data imply that mutation of one allele 
precedes mitotic recombination, which acts as a "second hit" responsible for 
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removal of the remaining wild-type allele which is substited by a copy of the 
mutated allele. Additional examples are the identification of UPD surrounding the 
NF1 gene locus in cases of juvenile myelomonocytic leukemia associated with 
neurofibromatosis.130 In lymphoma, the mutation status of genes within areas of 
UPD is less established, although bi-allelic mutations of P53 and P16/ARF have 
been reported in cases with UPD of 17p and 9p, respectively. SNP-CGH arrays 
described that in mantle cell lymphoma and in follicular lymphoma, most areas of 
UPD were coincident with known regions of chromosome deletion.104,105,131 
However, UPD was also observed in chromosome 6p in 20-30% of initial 
biopsies from patients with follicular lymphoma, an area not usually targeted by 
DNA copy number changes. To date, the gene or genes involved in this area 
have not been yet detected.104,105   

A different application of high-density SNP-CGH arrays has been the genome-
wide linkage search of 206 families with B-CLL. These studies indentified 
potential susceptibility loci on chromosomes 2q21.2, 6p22.1 and 18q21.1. 
Notably, none of the regions coincided with areas of common chromosomal 
abnormalities frequently observed for B-CLL.132 These findings strengthen the 
argument for an inherited predisposition to B-CLL that might explain familial 
aggregation, and support similar microarray studies in other familial cancers with 
unknown causing genes. 
 
4. INTEGRATIVE ONCOGENOMICS AS A TOOL TO DISCOVER NOVEL 
CANCER GENES 
 
Initial comparative genomic studies evaluated the degree to which DNA copy 
number alterations contributes to variations in the transcriptional program of 
tumors.133 Using cDNA microarrays, Pollack and colleagues found that 62% of 
highly amplified genes in breast tumors showed moderately or highly elevated 
expression. However, the influence of low-level DNA copy number changes was 
much more limited and only 12% of all the variation in gene expression among 
the breast tumors was directly attributable to underlying genomic dosage.134 
Using again beast cancer as a model disease, Hyman and colleagues reported 
that both high- and low-level copy number changes had a substantial impact on 
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gene expression, with 44% of the highly amplified genes showing overexpression 
and 10.5% of the highly overexpressed genes being amplified.135 A third study 
focused on the process of transformation of follicular lymphoma (FCL) to DLBCL, 
which is observed in over one-third of patients with FCL and is generally 
characterized by an aggressive clinical course and refractoriness to treatment. 
Parallel array-CGH and gene expression analyses revealed that FCL 
transformation was accompanied with a variable spectrum of recurrent genomic 
imbalances and gene expression changes. Among the ∼600 genes that 
presented deregulated expression in the transformation phase, up to one-third 
showed correlation with DNA copy number variation.136 Overall, these reports 
concluded that a fraction of transcriptomic modifications are consequence of 
genomic changes in tumors. 
 
Since these studies, more sophisticated bioinformatic methods were developed 
for determinig if altered patterns of gene expression correlate with chromosomal 
abnormalities. One of these softwares is ChARM (Chromosomal Aberration 
Region Miner), a robust and accurate expectation-maximization based method 
for identification of segmental aneuploidies from gene expression and array CGH 
microarray data, sensitive enough to detect statistically significant and 
biologically relevant subtle changes in mixed populations of cells.137 Likewise, 
DIGMAP is a powerful computational tool enabling the coupled analysis of 
microarray data with genome location.138 More complex devices include VAMP 
softwares (Visualization and Analysis of array-CGH, transcriptome and other 
Molecular Profiles), developed as a graphical user interface for visualization of 
CGH arrays, transcriptome arrays, SNP-CGH arrays, loss of heterozygosity 
results (LOH), and Chromatin ImmunoPrecipitation arrays. The interface offers 
the possibility of looking for recurrent regions of alterations, confrontation to 
transcriptome data or clinical information, and clustering.139 ARACNE is a 
different algorithm designed to scale up to the complexity of cellular regulatory 
networks present in microarray profiles, based on a theoretic approach that 
eliminates indirect interactions inferred by co-expression methods. For instance, 
authors demonstrated and validated a complex interactive network among the 
transcriptional targets of the c-MYC oncogene in B-cell lymphomas.140 
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One of the major advances of integrative oncogenomic approaches has been the 
identification of novel cancer genes. In one landmark report, Garraway and 
colleagues identified MITF (microphthalmia-associated transcription factor) as 
the target gene of a melanoma amplification by integrating SNP-CGH array maps 
with gene expression signatures derived from the NCI60 cell lines. Further 
investigation demonstrated that MITF represents a 'lineage survival' oncogene 
required for both melanoma development and metastatic spread.141 In the study 
by Yu and colleagues, the power of integrating multiple diverse genomic data of 
prostate cancer models (in vitro cell line, in vivo tumor profiling, and genome-
wide location data) to search for key targets genes of the Polycomb family 
protein EZH2, showed ADRB2 gene as a critical mediator of beta-adrenergic 
signaling.142 A number of additional papers have applied similar genetic screens 
to mouse models of cancer to discover new oncogenes. In a screen for gene 
copy-number changes in mouse mammary tumors, a 350-kb amplicon from a 
region syntenic to a locus amplified in human cancers at chromosome 11q22 
was detected. This amplicon contained only one gene, YAP, which encodes the 
mammalian ortholog of Drosophila Yorkie (Yki), resulted a regulator of cellular 
proliferation and apoptosis in epithelial cells.143 In a mouse model of 
hepatocarcinoma, genome-wide analyses of tumors revealed a similar 
amplification at mouse chromosome 9qA1 syntenic to human chromosome 
11q22. Gene-expression analyses delineated cIAP1 and YAP as candidate 
oncogenes that cooperated to promote tumorigenesis.144 A different study 
characterized metastatic variants in an induced mouse model of melanoma, 
identifying an acquired focal chromosomal amplification that corresponded to a 
much larger amplification in chromosome 6p25 in human metastatic melanomas. 
Further investigation demonstrated that NEDD9, the only gene within the minimal 
common region that exhibited amplification-associated overexpression, was a 
bona fide melanoma metastasis oncogene.145 Through the analysis of human 
and mouse models of B-cell lymphoma, Chang and colleagues demonstrated 
that c-MYC regulates a much broader set of miRNAs than previously anticipated. 
Notably, MYC over-expression promoted a widespread repression of miRNA 
expression, primarily through direct binding to miRNA promoters.146 An important 
advantage of the simultaneous study of human and mouse tumors is that 
putative candidate genes can be functionally validated in vivo. 
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The identification of tumor-suppressor genes in cancer by classical genetics 
methods has been difficult and slow. In one report, integration of genomic and 
gene-expression microarray data was applied to localize suppressor genes. 
Within 20 homozygous deletion areas detected in 48 human B-cell lymphoma 
cell lines, a number of novel candidate genes were pinpointed.100 Notably, some 
of these genes were shown to be inactivated in lymphoma biopsies by various 
genetic and epigenetic mechanisms that substantially varied among the different 
lymphoma subgroups. Thus, the P53-inducible PIG7/LITAF was silenced by 
homozygous deletion in primary mediastinal B-cell lymphoma and by promoter 
hypermethylation in germinal center lymphoma, whereas the proapoptotic BIM 
gene presented homozygous deletion in mantle cell lymphoma and promoter 
hypermethylation in Burkitt lymphoma.100 A different study evaluated the 
candidate target genes in chromosome 8p21.3 deletions delineated through high-
resolution array-CGH of B-cell lymphomas. In previous report, the presence of 
deletions of 8p in mantle cell lymphoma was associated with blood 
dissemination.83,147 By comparing gene expression profiles of tumors with and 
without 8p deletion, authors found that only two genes within the 8p21.3 deletion, 
those encoding for the TRAIL receptors R1 and R2, showed significant 
downregulation in deleted tumors.148 However, a recent report discovered that 
deletion of BIN3, another gene included within the 8p21.3 commonly deleted 
region, generated B-cell lymphoma in aging mice.149 Loss of BIN3, which is a 
BAR adapter protein, did not affect normal cell proliferation but rather increased 
the motility of transformed cells. It is tempting to speculate that the loss of BIN3 
may enhance B-cell lymphocyte migration, leading to a disseminated disease in 
patients with mantle cell lymphoma. A similar integrative microarray analysis 
revealed down-regulation of the gene encoding P53-binding protein 1 (53BP1) in 
DLBCL with heterozygous deletion of chromosome 15q15, being this deletion 
more common in the BCR-DLBCL group.150 Although a reduced gene and 
protein dosage (happloinsufficiency) caused by the single-copy loss is suggested 
as the tumoral pathogenetic mechanism in these reports, further investigations 
are needed to validate this attractive hypothesis. 
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A different strategy combined nonsense-mediated RNA decay microarrays and 
array-CG for the genome-wide identification of genes with biallelic inactivation 
involving nonsense mutations and loss of the wild-type allele. This approach 
enabled the authors to identify previously unknown inactivating mutations in the 
receptor tyrosine kinase gene EPHB2, which were shown to be functionally 
important in the progression and metastasis of prostate cancer.151 Zardo and 
colleagues used an alternative approach that integrated array-CGH and 
restriction landmark genomic scanning for global analysis of aberrant methylation 
of CpG islands in a series of human glioblastomas.152 Results showed that most 
aberrant methylation events are focal and independent of genomic deletions, but 
a small subset of genes were affected by convergent methylation and deletion, 
including genes that exhibit tumor-suppressor activity such as  such as SOCS1 
and COE3. In a different study, Stransky and colleagues used a combination of 
transcriptome correlation map analysis and array-CGH to evaluate at a large 
scale epigenetic suppression of gene expression of whole genomic regions. 
Authors demonstrated such regional copy number-independent deregulation of 
transcription by long-range epigenetic silencing in a series of bladder 
carcinomas.153 In another study, authors determined the expression profiling of 
microRNAs in T24 cells, revealing that 17 out of 313 miRNAs were upregulated 
after DNA demethylation and histone deacetylase inhibition treatment. One of 
these, miR-127, was shown to repress BCL6 oncogene, suggesting a role in the 
pathogenesis of this disease.154 
 
Multiple myeloma is one of the tumors where integrative oncogenomic 
approaches have been more successfully applied. Shaughnessy and colleagues 
performed microarray analysis on myeloma cells from 532 patients. Seventy 
genes, 30% of them mapping to chromosome 1, were linked to reduced length of 
survival. Importantly, most up-regulated genes mapped to chromosome 1q 
(frequently amplified in myeloma), and down-regulated genes mapped to 
chromosome 1p (frequently deleted in myeloma). These data suggest that 
altered transcriptional regulation of chromosome 1 genes contribute to multiple 
myeloma pathogenesis and can be used to identify high-risk disease.60 In a 
different study, high-resolution array-CGH data and expression profiles were 
determined in a collection of myeloma cell lines and patient biopsies. 
 
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Unsupervised classification defined distinct genomic subtypes. Genomic and 
expression data integration generated a refined list of myeloma gene candidates, 
thereby providing a molecular framework for dissection of disease 
pathogenesis.155 More recently, two different groups investigated possible 
genetic lesions responsible for the constitutive NF-kB activation observed in 
multiple myeloma by integrating array-CGH and gene expression profiling data. 
Keats and colleagues found mutations in ten genes causing the inactivation of 
TRAF2, TRAF3, CYLD, cIAP1/cIAP2 and activation of NFKB1, NFKB2, CD40, 
LTBR, TACI, and NIK that result primarily in constitutive activation of the 
noncanonical NF-kB pathway, with the single most common abnormality being 
inactivation of TRAF3.156 Annunziata and colleagues compared the genetic 
profiles of multiple myeloma cell lines that were resistant or sensitive to an 
inhibitor of IkappaB kinase beta (IKKbeta) targeting the NF-kB pathway. 
Sensitive cell lines with NF-kB activation showed frequent genetic or epigenetic 
alteration of NIK, TRAF3, CYLD, cAPI1/cAPI2, CD40, NFKB1, or NFKB2 
genes.157 These two complementary reports uncovered frequent genetic lesions 
of genes in the NF-kB pathway, suggesting that NF-kB inhibitors hold promise for 
the treatment of this disease. 
 
5. FUTURE INVESTIGATIONS: INTEGRATIVE COMPUTATIONAL ANALYSIS 
OF NOVEL HIGH-THROUGHPUT GENETIC TECHNOLOGIES IN CANCER 
BIOLOGY 
 
A miriad of new high-throughput technologies are being used in cancer research, 
including exon arrays to analyze alternative splicing, tiling arrays for high-
resolution investigation of DNA and histone methylation patterns, on-chip 
chromatin immunoprecipitation to discover DNA-protein interactions and protein 
microarrays to measure global protein expression portraits. Consequently, next 
comparative oncogenomic and proteomic assays will attempt to viualize these 
complex molecular interactions in the context of highly connected and regulated 
cellular networks. While we assist to these fantastic advances, our last challenge  
is to use this comprehensive biological knowledge to accelerate the transition 
from current empirical therapies to tailored medicine. 
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
6. MATERIALS  
 
TOTAL RNA PREPARATION FOR MICROARRAY ANALYSIS 
 
This protocol is suitable for total RNA sample preparation for microarray 
analysis from cell lines or fresh frozen tissues. RNA obtained this way is very 
clean and salt free. 
 
MATERIALS 
Reagents 
• TRIzol® Reagent, Invitrogen Life Technologies, P/N 15596-018 
• RNeasy® Mini Kit, QIAGEN, P/N 74104 
Contains: 
Rneasy® Mini Spin columns 
RLT buffer 
RPE buffer 
RNase-free water 
• Absolute ethanol (store ethanol at room temperature) 
• 80% ethanol (store ethanol at room temperature) 
Supplies 
• IKA® T-10 Basic Homogenizer (for fresh frozen tissue) 
• Nanodrop ND-1000 Spectrophotometer 
• 2100 Bioanalyzer and Agilent, RNA 6000 Nano LabChip® kit, P/N 5067-1511 
 
PROCEDURES 
1a. For fresh frozen tissue samples: The amount of tissue required is variable 
depending on the kind of tissue and varies from 10 to 100 mg to get 10-300 µg 
of total RNA. Be careful not to let tissue thaw before homogenization. 
Homogenize tissue directly in TRIzol® reagent using an electric homogenizer by 
means of a small gauge generator (5 mm). Recommended volume of TRIzol® is 
1 mL for each 50-100 mg of tissue. Homogenize each sample tube at least 3 
times for at least 1 minute each time. Keep the samples on ice in between each 
 
round of homogenization because overheat of samples can cause RNA 
degradation. 
1b. For cell lines: Pellet cells by centrifugation and completely remove culture 
medium. Do not wash cells at this moment, proceed directly to lyse cells with 
the appropriate amount of TRIzol® reagent (recommended by manufacturer 1 
mL/5-10×106 cells) by pipetting. 
2. Let the samples stand for 5 minutes at room temperature. 
3. Pass the sample twice through a 25G needle in order to reduce viscosity of 
the sample. 
4. Add 200 µL of chloroform per mL of TRIzol® used and shake the sample for 
15 s vigorously by hand. Incubate for 1 minute and shake again for 15 s. 
5. Centrifuge the sample at 12,000 x g for 15 minutes at 2-8 °C. 
6. Following centrifugation the mixture separates into two phases, the 
colourless upper one is the aqueous phase where there is the RNA. The other 
one is the pink-phase (phenol-chloroform) which contains DNA and proteins. 
Take 200 µL from the top layer to continue and add them to 700 µL of QIAGEN 
RLT buffer in a new RNase-free tube. (Do not add 2-mercaptoethanol to RLT 
buffer because it may increase background in the array). 
7. Add 500 µL of absolute ethanol to the sample (200 µL + 700 µL RLT). Mix 
well by vortex. 
8. Apply the mixture to a QIAGEN Mini or MicroElute spin column and spin 15 s 
at 8,000 x g. Discard the flow through and repeat the procedure until all the 
sample has been loaded onto the column. 
9. Replace the collector tube for a new one and wash the column by adding 500 
µL of the RPE buffer. Centrifuge 15 s at 8,000 x g and discard flow through. 
10. Add 700 µL of 80% ethanol and spin at 8,000 x g 15 s. Repeat this step 
again to efficiently remove all guanidine salts. 
11. Transfer the column to a new collector tube and spin for 5 min at top speed 
with tubes cap off to ensure removal of ethanol. 
12. To elute RNA, transfer the column to a new 1.5 mL RNase-free microfuge 
tube. Elute with 20 µL or 14 µL of RNase-free water for Mini or MicroElute Spin 
column, respectively. 
 
QUALITY CONTROL OF RNA 
 
 
To qualify RNA for microarray applications it is important to measure its 
concentration, 260/280 ratio, 260/230 ratio and RNA integrity. We use 
Nanodrop to asses that the concentration is at least 250 ng/µL, the 260/280 
ratio is between 1.9-2.1; and the 260/230 ratio is greater than 1.5 (this 
determines the presence of salts that could inhibit labelling reactions). Integrity 
of RNA can be measured by studying integrity of rRNA on gel. Affymetrix 
recommends the use of the capillary electrophoresis Bioanalyzer 2100 system 
from Agilent. This software calculates the RIN (RNA Integrity Number), which in 
our experience should be greater than 8.0 to guarantee that the sample will 
work properly on the array. 
 
DNA PREPARATION FOR MICROARRAY ANALYSIS 
 
This protocol is based on the procedure established by QIAGEN using their 
DNeasy® Blood & Tissue kit. 
 
MATERIALS 
Reagents 
• DNeasy® Blood & Tissue kit, QIAGEN, P/N 69504 
Contains: 
Dneasy® Mini Spin columns 
ATL buffer 
Proteinase K 
AL buffer 
AW1 buffer 
AW2 buffer 
• Absolute ethanol 
• Reduced EDTA TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0) 
Supplies 
• Nanodrop ND-1000 Spectrophotometer 
 
PROCEDURE 
For tissue samples: 
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1a. The amount of tissue needed is variable but 25 mg tissue (up to 10 mg 
spleen) maybe suitable for this application. Cut the tissue into small 
pieces, and place it in a 1.5 mL microcentrifuge tube. Add 180 L Buffer 
ATL. 
2a. Add 20 µL proteinase K. Mix thoroughly by vortexing, and incubate at 55 
°C until the tissue is completely lysed (it can be lysed overnight). During 
incubation it is recommended to vortex occasionally to disperse the 
sample. 
3a. Add 200 µl Buffer AL to the sample, and mix thoroughly by vortexing. 
Then add 200 µL ethanol (96–100%), and mix again by vortexing. It is 
essential that the sample, Buffer AL, and ethanol are mixed immediately 
and thoroughly to yield a homogeneous solution. 
For cell lines: 
1b. Start from around 5x106 cells, pellet them and wash twice with 1X PBS. 
Resuspend pellet in 200 µL 1X PBS. 
2b. Add 20 µL proteinase K and 200 µL of buffer AL mix thoroughly by 
vortexing and place at 70 °C for 10 minutes. 
3b. Then add 200 µL ethanol (96–100%), and mix again thoroughly by 
vortexing.
4. Pipet the sample (including any precipitate) into the DNeasy® Mini spin 
column placed in a 2 mL collection tube. Centrifuge at 6,000 x g for 1 min. 
Discard flow-through and collection tube. 
5. Place the DNeasy® Mini spin column in a new 2 mL collection tube, add 500 
µL Buffer AW1, and centrifuge for 1 min at 6,000 x g. Discard flow-through 
and collection tube. 
6. Place the DNeasy® Mini spin column in a new 2 mL collection tube, add 500 
µL Buffer AW2, and centrifuge for 3 min at 20,000 x g to dry the DNeasy® 
membrane. Discard flow-through and collection tube. 
7. Place the DNeasy® Mini spin column in a clean 1.5 mL or 2 mL 
microcentrifuge tube, and pipet 200 µL Buffer AE directly onto the DNeasy® 
membrane. Incubate at room temperature for 1 min, and then centrifuge for 
1 min at 6,000 x g to elute. If SNP arrays from Affymetrix are to be 
performed, then use a buffer with lower EDTA concentration to elute the 
 
sample (10 mM Tris-HCl; 0.1 mM EDTA pH 8.0) as EDTA concentration 
adversely affects following reactions. 
 
QUALITY CONTROL OF DNA 
 
Principal parameters to control DNA quality are concentration (for 500K SNP 
array from Affymetrix it should be at least 50 ng/µL), 260/280 ratio around 1.9 if 
pure DNA and 260/230 ratio greater than 1.5 in salt-free samples. To determine 
DNA integrity, we perform gel electrophoresis on a 1-2% agarose 1X TBE gel. 
High quality genomic DNA will give a band of 10-20 Kb on the gel. 
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7. METHODS FOR RNA AND DNA MICROARRAYS 
 
Oligonucleotide gene expression microarrays 
 
Introduction 
We use the One-Cycle Eukaryotic Target Labelling Assay from Affymetrix. It is 
possible to start with total RNA (1 µg to 15 µg) or mRNA (0.2 µg to 2 µg). We 
normally begin with 2 µg of total RNA. It is fundamental to start with the same 
amount of RNA for all samples to be compared. This RNA is first reverse 
transcribed using a T7-Oligo(dT) Promoter Primer. Second-strand synthesis 
reaction is mediated by RNase H. Double-stranded cDNA obtained is then 
purified and used as a template in the following in vitro transcription (IVT) 
reaction. The IVT reaction is performed in the presence of T7 RNA Polymerase 
and a biotinylated nucleotide analog/ribonucleotide mix for complementary RNA 
(cRNA) amplification and biotin labelling. This biotinylated cRNA targets are 
then cleaned up, fragmented, and hybridized to GeneChip expression arrays. 
 
Materials 
 
Reagents 
 Labelling 
• One-Cycle Target Labelling and Control Reagents, Affymetrix, P/N 
900493 
• Contains: 
• 1 IVT Labelling Kit (Affymetrix, P/N 900449) 
• 1 One-Cycle cDNA Synthesis Kit (Affymetrix, P/N 900431) 
• 1 Sample Cleanup Module (Affymetrix, P/N 900371) 
• 1 Poly-A RNA Control Kit (Affymetrix, P/N 900433) 
• 1 Hybridization Control Kit (Affymetrix, P/N 900454) 
• Absolute ethanol 
• 80% ethanol 
Hybridization, Stain and Wash 
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• GeneChip Hybridization, Wash and Stain kit, Affymetrix, P/N 900720 (30 
reactions) 
• Contains: 
• Hybridization module (Pre-Hybridization mix, 2X Hybridization mix, 
DMSO, Nuclease-free water) 
• Stain Module (Stain Cocktail 1, Stain Cocktail 2, Array Holding Buffer) 
• Wash Buffers (Wash Buffer A, Wash Buffer B) 
• GeneChip Eukaryotic Hybridization Control Kit, Affymetrix, P/N 900454 
(30 reactions) or P/N 900457 (150 reactions), contains Control cRNA and 
Control Oligo B2 
Supplies 
• Nanodrop ND-1000 Spectrophotometer 
• 2100 Bioanalyzer and Agilent, RNA 6000 Nano LabChip® kit, P/N 5067-
1511 
• Hybridization Oven 640, Affymetrix, P/N 800138 (110V) or 800139 (220V) 
• Heatblock 
• Fluidics Station 450: Affymetrix, P/N 00-0079 
• GeneChip® Scanner 3000: Affymetrix, P/N 00-00212 
 
Procedures 
 
Preparation of Poly-A RNA Controls for One-Cycle cDNA Synthesis 
(Spike-in Controls) 
Relative amount of Poly-A RNA Controls added to the sample RNA will be 
constant, therefore it is dependent on the initial µg of sample. For 2 µg of RNA, 
2 µL of a 1:50,000 dilution of Poly-A RNA Controls are used. 
 
First-Strand cDNA Synthesis 
1. Mix RNA sample, diluted poly-A RNA controls, and T7-Oligo(dT) Primer. 
Incubate the reaction for 10 minutes at 70 °C. Then cool the sample at 4 
°C for at least 2 minutes. 
2. In a separate tube, assemble the First-Strand Master Mix: 4.0 µL 5X 1st 
Strand Reaction Mix; 2.0 µL 0.1 M DTT; 1 µL 10 mM dNTP (per sample). 
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3. Transfer 7 µL of First-Strand Master Mix to each RNA/T7-Oligo(dT) Primer 
mix for a final volume of 19 µL. Mix by flicking the tube a few times. 
Immediately place the tubes at 42 °C and incubate for 2 minutes at 42 °C. 
4. Add 1 µL of SuperScript II to each RNA sample for a final volume of 20 L. 
5. Incubate for 1 hour at 42 °C; then cool the sample for at least 2 minutes at 
4 °C. 
 
Second-Strand cDNA Synthesis 
1. Prepare Second-Strand Master Mix: 91 L RNase-free Water; 30 L 5X 
2nd Strand Reaction Mix; 3 L 10 mM  dNTP; 1 L E. coli DNA ligase; 4 
L E. coli DNA Polymerase I; 1 L RNase H (per sample). 
2. Add 130 L of Second-Strand Master Mix to each first-strand synthesis 
sample from First-Strand cDNA Synthesis for a total volume of 150 L. 
Then incubate for 2 h at 16 °C. 
3. Add 2 L of T4 DNA Polymerase to each sample and incubate for 5 
additional minutes at 16 °C. 
4. Then add 10 L 0.5 M EDTA and proceed to Cleanup of Double-Stranded 
cDNA. Do not leave the reactions at 4 °C for long periods of time. 
 
Cleanup of Double-Stranded cDNA 
1. Add 600 L of cDNA Binding Buffer to the double-stranded cDNA 
synthesis preparation and mix by vortexing for 3 seconds. Colour of the 
mixture should be yellow. If not add 10 L of 3 M sodium acetate pH 5.0, 
and mix. 
2. Apply 500 L of the sample to the cDNA Cleanup Spin Column sitting in a 
2 mL Collection Tube, and centrifuge for 1 minute at  8,000 x g. Discard 
flow-through. Repeat reload of the spin column with the remaining mixture 
and centrifuge as above. Discard flow-through and Collection Tube. 
3. Transfer spin column into a new 2 mL Collection Tube. Wash spin column 
with 750 L of the cDNA Wash Buffer. Centrifuge for 1 min at  8,000 x g. 
Discard flow-through. 
4. Open the cap of the spin column and centrifuge for 5 min at maximum 
speed to completely eliminate ethanol. Discard flow-through and 
Collection Tube. 
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5. Transfer spin column into a 1.5 mL Collection Tube, and pipet 14 L of 
cDNA Elution Buffer directly onto the spin column membrane. Incubate for 
1 minute at room temperature and centrifuge 1 min at maximum speed 
(25,000 x g) to elute. 
 
Synthesis of Biotin-Labeled cRNA 
1. Transfer the needed amount of template cDNA (if 2 µg were used as 
starting material, use 12 µL of purified cDNA) to RNase-free microfuge 
tubes and add the following reaction components in the order indicated: 8 
L RNase-free Water; 4 L 10X IVT Labelling Buffer; 12 L IVT Labelling 
NTP Mix; 4 L IVT Labelling Enzyme Mix. It is important not to assemble 
the reaction on ice, because spermidine in the 10X IVT Labeling Buffer 
can lead to precipitation of the template cDNA. 
2. Incubate at 37 °C for 16 h in a thermal cycler. 
 
Cleanup and Quantification of Biotin-Labeled cRNA 
1. Add 60 L of RNase-free Water to the IVT reaction and mix by vortexing 
for 3 s. 
2. Add 350 L IVT cRNA Binding Buffer to the sample and mix by vortexing 
for 3 s. 
3. Add 250 L ethanol (96-100%) to the lysate, and mix well by pipetting. Do 
not centrifuge at this step. 
4. Apply sample (700 L) to the IVT cRNA Cleanup Spin Column sitting in a 
2 mL Collection Tube. Centrifuge for 15 s at  8,000 x g. Discard flow-
through and Collection Tube. 
5. Transfer the spin column into a new 2 mL Collection Tube. Pipet 500 L 
IVT cRNA Wash Buffer onto the spin column. Centrifuge for 15 seconds at 
 8,000 x g to wash. Discard flow-through. 
6. Pipet 500 L 80% (v/v) ethanol onto the spin column and centrifuge for 15 
seconds at  8,000 x g. Discard flow-through. 
7. Centrifuge for 5 minutes with caps off at maximum speed to allow 
complete drying of the membrane. Discard flow-through and Collection 
Tube. 
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8. Transfer spin column into a new 1.5 mL Collection Tube, and pipet 21 L 
of RNase-free Water directly onto the spin column membrane. Centrifuge 
1 min at maximum speed ( 25,000 x g) to elute. 
For subsequent quantification of the purified cRNA, we dilute the eluate 1:5 or 
1:4 fold in RNase-free water. We use Nanodrop to determine concentration of 
the cRNA obtained and Bioanalyzer to study sizes of the labelled products 
(which should have an average size of 1580 nucleotides). 
If using total RNA as starting material, it is necessary to calculate an adjusted 
cRNA yield to reflect carryover of unlabeled total RNA. Using an estimate of 
100% carryover, use the formula below to determine adjusted cRNA yield: 
adjusted cRNA yield = RNAm - (total RNAi) (y) 
RNAm = amount of cRNA measured after IVT (g) 
total RNAi = starting amount of total RNA (g) 
y = fraction of cDNA reaction used in IVTSample Cleanup Module 
 
Fragmenting the cRNA for Target Preparation 
1. Fragmentation of cRNA is a critical step of the protocol. When using a 49 
microarray format, we will fragment 20 g (with a volume ranging from 1 to 
21 L). Final volume of fragmentation reaction is 40 µL where 8 µL 
correspond to 5X Fragmentation Buffer. 
2. Incubate reaction at 94 °C for 35 minutes. Put on ice following the 
incubation. 
 
Save an aliquot for analysis on the Bioanalyzer. This standard fragmentation 
procedure should produce a distribution of RNA fragment sizes from 
approximately 35 to 200 bases. 
Undiluted, fragmented sample cRNA is ready to perform the hybridization. If you 
are not going to proceed with labelling at the moment store the sample at -20 °C 
(or -70 °C for longer-term storage). 
 
Hybridization 
1. Mix the following for each target, scaling up volumes for hybridization to 
multiple probe arrays.  
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15 g Fragmented cRNA (final concentration 0.05 g/L) 
5 L Control Oligonucleotide B2 3 nM (final concentration 50 pM) 
15 L 20X Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre) 
(final concentration 1.5 pM) 
150 L 2X Hybridization Buffer (final concentration 1X) 
30 L DMSO (final concentration 10%) 
Nuclease-free water up to 300 µL 
2. Equilibrate probe array to room temperature immediately before use. 
3. Heat the hybridization cocktail to 99 °C for 5 minutes in a heat block. 
4. Meanwhile, wet the array by filling it through one of the septa with 
appropriate volume of 1X Pre-Hybridization Buffer using a micropipettor 
and appropriate tips. Incubate the probe array at 45 °C for 10 minutes with 
rotation. 
5. Transfer the hybridization cocktail that has been heated at 99 °C, in step 
3, to a 45 °C heat block for 5 minutes. 
6. Spin hybridization cocktail(s) at maximum speed in a microcentrifuge for 5 
minutes to remove any insoluble material from the hybridization mixture. 
7. Remove the buffer solution from the probe array cartridge and fill with 200 
µL (for the 49-format) of the clarified hybridization cocktail, avoiding any 
insoluble matter at the bottom of the tube. 
8. Place probe array into the Hybridization Oven, set to 45 °C. Avoid stress 
to the motor; load probe arrays in a balanced configuration around the 
axis. Rotate at 60 r.p.m. Hybridize for 16 hours. 
 
Staining, washing and scanning 
Staining and washing are performed using the Fluidics Station 450 (Affymetrix). 
At this point, the most important is to select the correct script for your chip. For 
example HUG-133 2.0 Plus uses protocol FS450_0001. The script contains the 
directions to stain and wash the microarray: number of cycles of wash or stain, 
temperature, buffer. 
For HUG-133 2.0 Plus place Stain Cocktail 1 in sample holder 1, Stain Cocktail 
2 in sample holder 2 and Array Holding Buffer in sample holder 3. In the final 
step, probe array is filled with array holding buffer; arrays can be stored for 3 
hours at 4 °C at dark before scanning. 
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The scanner used is GeneChip® Scanner 3000. Complete image of scanned 
array is stored as a .DAT file (scanned image, full information), and then GCOS 
software generates the .CEL file which represents the first summarization step 
because image is summarized in median intensity/probe cell. 
 
CGH to BAC microarrays 
 
Introduction 
The arrays for CGH consist of linker-adapter PCR representation of BAC clones 
printed on a substrate. Each clone contains at least one STS (Sequence 
Tagged Site) and is mapped to the human genome sequence. Clones 
containing unique sequences near telomeres and clones containing genes 
known to be significant in cancer and medical genetics are included. 
Hybridization to these arrays allows detection of single copy gains and losses 
compared to diploid cells even in presence of normal cell contamination. 
 
Materials 
Random primed labeling of genomic DNA for array CGH analysis 
• 2.5X Random Primers (BioPrime DNA labeling systems, Invitrogen 
18094-011). Store a -20 °C. 
• Genomic DNA. 
• Klenow fragment (40 U/ µL, BioPrime DNA labeling system, Invitrogen 
18094-011). Store a -20 °C. 
• Cy3 and Cy5 labeled dCTP (1 mM, Amersham Pharmacia Biotech Inc. 
PA53021 and PA55021). 
• 0.5 M EDTA, pH 8.0. 
• 1 M Tris-HCl, pH 7.6. 
• 10X dNTP mixture  in sterile water: 3.7 mM dATP, dTTP and dGTP 
(Invitrogen, 10216-018, 10219-012 and 10218-014, respectively),  1.8 mM 
dCTP (Invitrogen 10217-016), 10 mM Tris-HCl pH 7.6 and 1 mM EDTA. 
• Sephadex G-50 spin column (Amersham Pharmacia Biotech Inc. 27-
5330-01). 
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Hybridization of fluorescently labeled genomic DNA for array CGH 
analysis 
• Human cot-1 DNA (1 mg/µL, Invitrogen) 
• 20% SDS in sterile H2O (heat at 68 °C to dissolve). 
• 100% Ethanol. Store ay -20 °C. 
• 3.0 M Sodium acetate, pH 5.2. 
• Dextran sulfate sodium salt (500,000 MW). 
• Formamide (re-destilled, ultra pure, Invitrogen). Store a -20 °C 
• 20X SSC (3.0 M NaCl, 0.3 M sodium citrate, pH 7.0). 
• Mastermix mixture: dissolve 1 g dextran sulfate in 5 mL of formamide, 1 
mL of 20X SSC and 1 mL dH2O. Adjust to pH 7.0 with approximately 2 
drops of HCl.  
• PN buffer: 0.1 M sodium phosphate, 0.1% Nonidet P40, pH 8.0. 
• UV Stratalinker 2400 (Stratagene) capable of producing 130,000 x 100 
µJoules UV. 
• Very slow rocking table (-1 rpm) inside a 37 °C incubator. 
• Rubber cement (Ross, American Glue Corporation). 
• Silicon gasket (Press-to-seal, 2 mm thick, #62-6508-24, PGC  Scientific). 
• 100% Glycerol 
• 10X PBS 
• Stereomicroscope. 
• Binder clips, medium size. 
Supplies 
• UV Stratalinker 2400 (Stratagene) 
• 1M Pixel CCD Imager (custom made; Dan Pincel, UCSF) or the 2-color 
scanner arrayWoRxe Biochip Reader (AppliedPrecision, Issaquah, 
Washington, USA), a white-light CCD-based system that provides  
highest quality images along with more accurate and repeatable 
microarray results. 
  
Procedures 
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Random primed labeling of genomic DNA for array CGH analysis  
A typical random primed labeling procedure is described. The random primed 
labeling is carried out in a 25 µL reaction volume containing:  600 ng genomic 
DNA, 1X random primers, 40 U Klenow DNA polymerase, Cy3 and Cy5 labeled 
dCTP and 1X dNTP mixture. 
1. Mix 6000 ng genomic DNA with 10 µL of 2.5X random primer solution 
and make up the volume to 21 µL with sterile H2O. 
2. Denature the DNA by heating the mixture at 99 C in a PCR machine for 
10 min. Briefly centrifuge and place on ice. 
3. Add: 2.5 µL of the 10X dNTP mixture, 1 µL of 1 mM Cy3 and Cy5 labeled 
dCTP and 0.6 µL Klenow DNA polymerase. Incubate at 37 °C for 12-20 
h.  
4. Remove unincorporated nucleotides from the DNA. 
Place a Sephadex G-50 column in a 1.5 mL tube and pre-spin the 
column at 760 x g for 1 min.  Discard the supernatant. Tap the end of the 
tube to a paper towel to remove the remaining supernatant from the neck 
of the tube.  Place the column in a clean 1.5 mL tube, apply the sample 
onto the column and spin at 760 x g for 2 min. 
 
Hybridization of fluorescently labeled genomic DNA for array CGH 
analysis 
1. Preparation of the array for the hybridization: 
a. Expose a printed array to 260,000 µJ (2,600 x 100 µJ) of UV by 
using a Stratalinker. Place the slide in the Stratalinker, array 
facing up. Overcrosslinking the slide might result in a decrease in 
fluorescent hybridization signal. 
b. Fill a 10 mL syringe with rubber cement and fit a 200 µL pipet tip 
on the syringe outlet. You may have to cut 1-2 mm off the wide of 
the pipet tip for it to fit well. Apply a rubber cement ring around 
each array on the slide using a stereomicroscope to observe the 
area of the array. Air-dry and apply a second thick layer of rubber 
cement on top of the first layer Air-dry the rubber cement. 
2. Preparation of samples for hybridization: 
 
a. Combine 25 µL labeled test genomic DNA, 25 µL labeled 
reference genomic DNA and 40-50 µg of human Cot-1 DNA. 
Precipitate the DNA sample mixture by adding 2.5 volumes of ice-
cold 100% ethanol and 0.1 volume of 3 M sodium acetate pH 5.2. 
Vortex the solution briefly and collect the precipitate by 
centrifugation at 14,000 x g for 45 min at 4 °C. 
b. Carefully aspirate and discard the supernatant. Wipe the excess 
liquid from the tube and air-dry the pellet for approximately 5-10 
min. Dissolve the pellet in 7 µL dH2O, 14 µL 20% SDS, and 49 µL 
Master mix mixture. Incubate 1 h at room temperature to 
completely resuspend. 
3.  Denature the DNA sample at 73 °C for 13 min and then incubate at 
37 °C for 1-2 h to allow the Cot-1 DNA to anneal to repetitive 
sequences. 
4. Place array on a heat block set at 37 °C for 5 min to warm the array. 
5. Apply the sample (step 3) onto the array. Keep the sample at 37 °C 
until just before application to the array to reduce non-specific binding 
of the probe to the array surface. Place a silicon gasket around the 
edge of the slide and lay a clean glass slide on top, aligning the 
edges with the gasket. Clamp the assembly together using binder 
clips. Incubate the array for 48-68 h at 37 °C on a slowly rocking table 
(--1 r.p.m.). 
6. Disassembly the array assembly and rinse the hybridization solution 
from the slide under a stream of PN buffer. It is preferred to leave the 
rubber cement on the array at this time, as it will not affect the rising 
steps that follow. 
7. Wash the slides once on 50% formamide, 2X SSC, pH 7.0 for 15 min 
at 45 °C, followed by a 15 min wash in PN buffer at room 
temperature. The washes can conveniently be done in slide staining 
jars (coupling jars) placed on water baths. 
8. At the bench, carefully remove the rubber cement with forceps, while 
keeping the array moist with PN buffer. 
9. Mount the slide in a DAPI solution to stain the array spots (90% 
glycerol, 10% PBS, 1 µM DAPI). 
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Microarray image capture with CCD Imager and microarray image 
quantification 
To capture the microarray image with CCD Imager for the image quantification 
we use the software “UCSF SPOT” available in 
www.janlab.org/downloads.htmL. This software allows the obtaining of 
numerical values, expressed in log2 ratio, for the ratios comprised between the 
sample to be analyzed and the control sample. The numerical data are 
processed and saved in an Excel table. Using the software “SPROC”, the data 
are normalized from the .spot files generating the final log2 ratio file data with 
the standard deviation (media of each three spots). At the same time, the 
program arranges the BACs by its genomic position and chromosome location 
(http//genome.vse.ucsc.edu) 
 
High resolution SNP-CGH microarrays 
 
Introduction 
The purpose of the Affymetrix GeneChip Mapping 500K Assay is to detect 
Single Nucleotide Polymorphisms (SNPs) greater than 500,000 in samples of 
genomic DNA. The Mapping 500K Set is comprised of two arrays and two 
assay kit. The protocol starts with 250 ng of genomic DNA per array and will 
generate SNP genotype calls for approximately 250,000 SNPs for each array of 
the two array set. The assay utilizes a strategy that reduces the complexity of 
the human genomic DNA up to 10 fold by first digesting the genomic DNA with 
the NspI or StyI restriction enzyme and then ligating sequences onto the DNA 
fragments. The complexity is further reduced by a PCR procedure optimized for 
fragments of a specified size range. After these steps the PCR products are 
fragmented, end-labeled, and hybridized to a Gene Chip array. 
 
Materials 
 
• Reduced EDTA TE Buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0): 
TEKnova, P/N T0223. 
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• 250 ng Genomic DNA per array working stock: 50 ng/µL. 
 
• StyI (10,000 U/mL): New England Biolabs (NEB), P/N R0500S 
• NspI (10,000 U/mL): New England Biolabs (NEB), P/N R0602L 
• AccuGENE® Water, Molecular Biology-Grade, Cambrex, P/N 51200 
• T4 DNA Ligase: New England Biolabs (NEB), P/N M0202L 
• Adaptor Nsp (50 µM): Affymetrix, P/N 900596 for 30 Rxns and P/N 
900697 for 100 Rxns. 
• Adaptor Sty (50 µM): Affymetrix, P/N 900597 for 30 Rxns and P/N 
900698 for 100 Rxns. 
• G-C Melt (5 M): Clontech, P/N 639238 
• dNTP (2.5 mM): Takara, P/N 4030, or Fischer Scientific, P/N TAK 4030 
• PCR Primer 002 (100 µM): Affymetrix, P/N 900595 for 30 Rxns and P/N 
900702 for 100 Rxns. 
• Clontech TITANIUM® Taq Polymerase (50x): Clontech, P/N 63920. 
• All purpose Hi-Lo DNA Marker: Bionexus, Inc., P/N BN2050 
• DNA amplification Clean-up kit, to be used with Affymetrix DNA products: 
Clontech, P/N 636974 (1 plate). The kit contains RB Buffer. 
• Fragmentation Reagent (DnaseI): Affymetrix, P/N 900131 
• 10x Fragmentation buffer: Affymetrix, P/N 900422 for 30 Rxns 
• 4% TBE Gel: BMA Reliant precast (4% NuSieve 3:1 Plus Agarose): 
Cambrex, P/N 54929 
• GeneChip® DNA Labeling Reagent (30 mM): Affymetrix, P/N  900778 for 
30 Rxns and P/N 900699 for 100 Rxns. 
• Terminal Deoxynucleotidyl Transferase (30 U/µL): Affymetrix, P/N 
900508 for 30 Rxns and P/N 900703 for 100 Rxns.  
• 5X Terminal Deoxynucleotidyl Transferase Buffer: Affymetrix, P/N 
900425 for 30 Rxns and P/N 900696 for 100 Rxns.  
• 5 M TMACL (Tetramethyl Ammonium Chloride): Sigma, P/N T3411 
• MES Hydrate Sigma Ultra: Sigma, P/N M5287 
• MES Sodium SALT: Sigma, P/N M5057 
• Denhardt’s Solution: Sigma, P/N D2532 
• HSDNA (Herring Sperm DNA): Promega, P/N D1815 
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• Human Cot-1 DNA®: Invitrogen, P/N 15279-011 
• Oligo control reagent, 0100 (OCR, 0100): Affymetrix. P/N 900541 for 30 
Rxns and 900701 for 100 Rxns. 
• GeneChip 250K Array (one per sample). 
 
Supplies 
• GeneAmp® PCR System 9700 Thermocycler by Applied Biosystems 
• GeneChip Hybridization oven 640. 
• Manifold-QIAvac multiwell unit: QIAGEN, P/N 9014579 
• Biomek® Seal and Sample aluminum foil lids: Beckman, P/N 538619 
• Jitterbug® 115 VAC: Boekel Scientific, P/N 130000 
• QIAGEN® Vacuum regulator: QIAGEN, P/N 19530 
 
Procedures 
 
STEP 1. Genomic DNA Preparation 
 
To minimize contamination of the simples, the use of two separate rooms to 
perform the assay is recomended: one is the pre-PCR clean room (or area for 
the DNA template and free of PCR products), and the other is the PCR-Staging 
room or main lab, where the rest of steps are performed. 
1. Thoroughly mix the genomic DNA by vortexing at high speed for 3 sec. 
2. Determine the concentration of each genomic DNA sample. 
3. Based on OD measurements, dilute each sample to 50 ng/µL using reduced 
EDTA TE buffer. 
 
STEP 2. Restriction enzyme digestion 
 
Before proceeding:  
- Program the thermal cycler in advance. Switch on the thermal cycler 10 
minutes before reactions are ready so that the lid is heated. 
- Reference Genomic DNA 103 is supplied in both the Sty and NSP GeneChip 
Mapping 250K Assay Kits. This DNA can be used as a positive control. 
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1. Depending on the restriction enzyme used, prepare the following Digestion 
Master Mix  ON ICE (for multiple samples, make a 5% excess): for the NspI 
digestion, 9.75 µL H2O; 2 µL 10X NE Buffer 2; 2 µL 10X BSA (1 mg/mL); 1 µl 
NspI (10 U/µl). For the StyI digestion, 9.75 µL H2O; 2 µL 10X NE Buffer 3; 2 µL 
10X  BSA (1 mg/mL); 1 µL StyI (10 U/µl). 
Note: The BSA is supplied as 100x (10 mg/mL), and needs to be diluted 1:10 
with molecular grade water before use. 
2. Add 5 µL of genomic DNA diluted to each tube. Total amount of genomic 
DNA is 250 ng for each restriction enzyme 
3. Aliquot 14.75 µL of the digestion master mix to each tube containing DNA. 
Mix gently and spin at 400 x g. 
4. Place the tubes in the thermal cycler and run the 500K Digest program: 37 
°C, 120 min; 65 °C, 20 min; hold at 4°C. 
Store the sample at -20 °C if not proceeding to the next step. 
 
STEP 3. Ligation 
 
Before proceeding: 
- Program the thermal cycler in advance. Switch on the thermal cycler 10 min 
before reactions are ready so that the lid is heated. 
- Ligase buffer contains ATP and should be thawed/held at 4 °C. Avoid multiple 
freeze-thaw cycles, according to vendor’s intructions. 
 
1. Depending on the restriction enyme used, in the pre-PCR area prepare the 
following Ligation Master Mix ON ICE (for multple samples, prepare a 5% 
excess): for NspI, 0.75 µL Adaptor Nsp 50 µM; 2.5 µL 10X T4 DNA Ligase 
Buffer; 2 µL T4 DNA Ligase (400 U/ µl). For StyI: 0.75 µL Adaptor Sty 50 µM; 
2.5 µL 10X T4 DNA Ligase Buffer; 2 µL T4 DNA Ligase (400 U/ µl). Total 
volume: 5.25 µL. 
2. Aliquot 5.25 µL of the Ligation Master Mix into each digested DNA simple. 
Add the 19.75 µL of the digested DNA until a total volume of 25 µL. Mix gently 
and spin at 400 x g for 1 min at 4 °C 
 

3. Place tubes in a thermal cycler and run the 500K Ligate program: 16 °C, 180 
min; 70 °C, 20 min; hold at 4 °C. 
Store samples at -20 °C if not proceeding to the next step within 60 minutes. 
4. Dilute each DNA ligation reaction by adding 75 µL of molecular biology grade 
water to the 25 µL (1/4 dilution). 
 
STEP 4: PCR 
 
Before proceeding: 
- Program the thermal cycler in advance. Switch on the thermal cycler 10 
minutes before reactions are ready so that the lid is heated. 
 
1. Prepare the following PCR master Mix ON ICE (3 PCR reactions per sample) 
in the pre-PCR clean room for NspI or StyI ligation reactions and vortex at 
medium speed for 2 seconds (for multiple samples, make a 5% excess): for one 
PCR: 39.5 µL H2O; 10 µL 10X Clontech TITANIUM® Taq PCR Buffer; 20 µL 5 M 
G-C Melt; 14 µL 2.5 mM dNTPs; 4.5 µL 100 µM PCR Primer 002; 2 µL 50X  
Clontech TITANIUM® Taq Polymerase. 
Note: 90 µg of PCR product is needed for fragmentation 
2. Transfer 10 µL of each diluted ligated DNA to the corresponding 3 PCR 
tubes. 
3. Add 90 µL PCR Master mix to obtain a total volume of 100 µL. 
4. Mix gently and spin samples at 400 x g for 1 min. 
5. Place in the thermal cycler in the main lab and run the 500K PCR program 
(optimized for the GeneAmp® PCR System 9700 Thermocycler): 94 °C, 3 min; 
30x (94 °C, 30 s; 60 °C, 45 s; 68 °C, 15 s); 68 °C, 7 min; hold at 4 °C. 
6. Run 3 µL of each PCR product mixed with 3 µL 2X Gel Loading Dye on 2% 
TBE gel at 120 V for 1 h. 
PCR products can be stored at -20 °C if not proceeding to the next step within 
60 min. 
 
STEP 5: PCR purification and elution with Clontech Clean-up plate 
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1. Connect a vacuum manifold to a suitable vacuum source able to maintain 
600 mbar aprox. 
2. Place a Clean-Up Plate on top of the manifold. Cover wells that are not 
needed with PCR plate cover. We recommend to cover the plate with the 
aluminum cover, and remove the portion of the cover corresponding to the 
probe wells. 
3. Add 8 µL of 0.1 M EDTA (diluted from the 0.5 M EDTA in water) to each PCR 
reaction. Seal plate with plate cover, vortex at medium speed for 2 seconds, 
and spin at 400 x g for 1 min. 
4. Cosolidate three PCR reactions for each sample into one well of the Clean-
Up plate. 
5. Apply a vacuum and maintain at 600 mbar until the wells are completely dry. 
6. Wash the PCR products by adding 50 µL molecular biology grade water and 
dry the wells completely (~ 20 min). Repeat this step 2 additional times for a 
total of three water washes. 
7. Switch off vacuum source and release the vacuum. 
8. Carefully remove the Clean-Up plate from the vacuum manifold and 
inmediately: 
a) blot the plate on a stack of clean absorbent paper to remove any liquid that 
might remain on the bottom of the plate. 
b) dry the bottom of each well with an absorbent wipe. 
9. Add 45 µL RB buffer to each well. Cover the plate with PCR plate cover film 
and seal tightly. Moderately shake the Cean-Up Plate on a Plate shaker, for 10 
minutes at room temperature. 
10. Recover the purified PCR product to clean tubes by pippeting the eluate out 
of each well and transferring it to the corresponding tube. 
 
STEP 6: Quantification of purified PCR products 
 
1. Add 2 µL of the purified PCR product to 198 µl molecular biology grade water 
and mix well. 
2. Read the absorbance at 260 nm. Ensure that the reading is in the 
quantitative range of the instrument (generally 0.2 to 0.8 OD). 
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3. Apply the convention* that 1 absorbance unit at 260 nm equals 50 µg/mL for 
double-stranded PCR products. 
* This convention assumes a path length of 1 cm. Consult your spectrophotometer handbook for 
further information. 
4. For fragmentation: 
a) Transfer 90 µg of each of the purified DNA samples to the corresponding 
wells of a new plate. 
b) Bring the total volume of each well up to 45 µL by adding the appropiate 
volume of RB buffer. 
c) Cover the plate with PCR plate cover film and seal tightly. 
d) Vortex at medium speed for 2 s, and spin down at 400 x g for 1 min. 
 
STEP 7: Fragmentation 
 
Before proceeding: 
- Pre-heat the thermal cycler to 37 °C before setting up the fragmentation 
reaction 
- Prepare the fragmentation dilution inmediately prior to use 
- Perform all the dilution, and mixing steps on ice 
 
1. Pre-heat thermal cycler to 37 °C 
2. Add 5 µL 10x Fragmentation Buffer to each sample (45 µL) in the 
corresponding tube ON ICE, giving a total volume of 50 µL. 
3. Examine the label of the GeneChip Fragmentation Reagent tube for U/µl 
definition, and calculate dilution. 
Y = number of µl of stock Fragmentation Reagent 
X = number of U of stock Fragmentation Reagent per µL (see label on the tube) 
0.05 U/µL = final concentration of diluted Fragmentation Reagent 
120 µL = final volume of diluted Fragmentation Reagent (enough for 20 Rxns) 
 
Y = 0.05 U/µL * 120 µL /x U/µL 
4. Dilute the stock of Fragmentation Reagent to 0.05 U/µL as follows: 
a) Place the water, Fragmentation Buffer and Fragmentation Reagent on ice 
b) Combine the reagents ON ICE in the order shown below.  
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c) Vortex at medium speed for 2 s. 
See an example of dilution as follow: 105 µL H2O; 12 µL 10X Fragmentation 
Buffer; 3 µL Fragmentation Reagent; giving a total volume of 120 µL 
5. Divide the Fragmentation Reagent in the tubes required 
6. Add 5 µL of diluted Fragmentation Reagent (0.05 U/µL) to the PCR samples 
tubes containing Fragmentation mix on ice. Pipet up and down several times to 
mix. The total volume for each sample is 50 µL. 
7.  Mix gently the tubes and spin briefly at 400 x g at 4 °C 
8. Place the samples in a pre-heated thermo cycler as quickly as possible, and 
run the 500K Fragment program: 37 °C, 35 min; 95 °C, 15 min; hold at 4 °C. 
9. Spin the samples to collect at the bottom of the tube 
10. Dilute 4 µL of fragmented PCR product with 4 µL gel loading dye and run on 
4% TBE gel. 
Proceed inmediately to the Labeling step, if the result matches the example 
below. 
 
STEP 8: Labeling 
 
Before proceeding: 
- Program the thermal cycler in advance. Switch on the thermal cycler 10 
minutes before reactions are ready so that the lid is heated. 
 
1. Prepare Labeling Mix ON ICE and vortex at medium speed for 2 seconds (for 
multiple samples, make a 5% excess): 14 µL 5X TdT Buffer; 2 µL  30 mM 
GeneChip® DNA Labeling Reagent; 3.5 µL TdT (30 U/µL). 
2. Aliquot 19.5 µL of Labeling Master Mix into the tubes containing 50.5 µL of 
fragmented DNA, giving a total volume of 70 µL. 
3. Mix gently the reaction and spìn at 400 x g for 1 min at 4 °C 
4. Run the 500K Label program: 37 °C, 4 h; 95 °C, 15 min; hold at 4 °C. 
5. Spin the plate briefly at 400 x g to collect the reaction at the bottom of the 
tube. Samples can be stored at -20 °C if not proceeding to the next step. 
 
STEP 9: Target Hybridization 
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Before proceeding: 
- It is important to alow the arrays to equilibrate to room temperature 
completely. Unwrap the array and leave on the bench top for 15 minutes. 
- DMSO is light sensitive. It should be contained in a dark glass bottle. 
- Preparation of the 12X MES Stock: 70.4 g MES Hydrate; 193.3 g MES Sodium 
salt; 800 mL molecular biology grade water. Mix and adjust volume to 1,000 mL. 
The pH should be between 6.5 and 6.7. Filter through a 0.2 µm filter. 
Do not autoclave. Store between 2 and 8 °C, and shield from light. 
 
1. Prepare the Hybridization Cocktail Master Mix in the order described. For 
multiple samples, prepare 5% excess: 12 µL 12X MES; 13 µL DMSO; 13 µL 
50X Denhardt’s Solution; 3 µL 0.5 M EDTA; 3 µL HSDNA (10 mg/mL); 2 µL 
OCR 0100; 3 µL Human Cot-1 DNA (1 mg/mL); 1 µL  3% Tween-20;  140 µL 5 
M TMACL. Mix well. 
2. Transfer each of the labeled samples to a 1.5 mL Eppendorf tube. Aliquot 
190 µL of the Hybridization Cocktail Master Mix into the 70 µL of labeled DNA 
samples, giving a final volume of 260 µL. 
3. Heat the 260 µL of hybridization mix and labeled DNA at 99 °C in a heat 
block for exactly 10 min to denature. 
4. Cool on crushed ice for 10 s. 
5. Spin briefly at 400 x g in a microfuge to collect any condensate. 
6. Place the tubes at 49 °C for 1 min. 
7. Inject 200 µL denatured hybridization cocktail into the array. 
8. Hybridize at 49 °C for 16 to 18 hours at 60 r.p.m. in the oven. The remaining 
hybridization mix can be stored at -20 °C for future use. 
 
Technical notes 
 
The source of RNA is a major determinant of the success for each individual 
microarray experiment. In this, between 10 to 50 µg of high-quality RNA (usually 
corresponding to a 50-100 mm3 tumor biopsy) is needed. Ideally, tumor biopsies 
frozen inmediately after surgical resection in liquid nitrogen (at least at -80 °C to 
prevent RNA degradation) should be used.158,159 This requirement limits the 
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study of large series of patient samples, most of which are not stored in adequate 
conditions, especially in retrospective analyses or in series of rare tumors that 
are collected from different institutions. In addition, this requirement makes 
problematic to obtain early tumors or biopsies obtained through minimally 
invasive methods such as fine-needle aspiration.159-161 An alternative method to 
preserve biological specimens involves suspending the tissue in a preservative 
such as RNAlater, followed by snap freezing of the tissue the next day. This 
method obviates the inmediate need for nitrogen liquid, preserves the integrity of 
RNA to be used in microarrays experiments.160  
 
Although there are novel methods to extract high-quality RNA from small tumor 
amounts (even from a single cell) and formalin-fixed tissues, the utility of these 
RNAs should be extensively evaluated and carefully validated in gene expression 
microarrays.160,162     
 
Tumors are composed of different cell types, including malignant cells, stromal 
and inflammatory cells and blood vessels. The proportion of these cell 
populations vary between and within tumors. Because this heterogeneity can 
complicate the interpretation of microarrays results, a careful selection of the 
tumors to be included in the study is an important step. In addition, a detailed 
histopathological analysis of each tumor sample is mandatory. In cases with low 
percentage of tumor cells, microdissection of the tumor cells in biopsies or cell 
sorting by flow cytometry in blood, marrow aspirates, effusions or disgregated 
lymph nodes may be a good choice.163,164 However, expression of the non-
malignant surrounding cells may also be informative, and in some situations the 
analysis of both isolated tumor cells and whole tumors may be a good choice.55 
One additional issue is the inclusion in the microarray study of normal cell 
populations to allow the comparisson of tumors genetic profiles with their putative 
cells of origin and with the normal surrounding cells.3,165 
 
In array-based CGH using BAC clones, several factors influence the success of 
the analysis. First, the general heterogeneity of the spotted BACs, which differ in 
the proportion of repetitive sequences and gene DNA contents, providing 
variable signal hybridization intensities. Second, like in gene expression 
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microarrays, the presence of “contaminating” non-tumoral surrounding cells in 
the sample. These normal cells have two DNA copies genome-wide (with the 
exception of X and Y chromosomes in males), and conversely to gene 
expression profiling, its analysis does not provide any biological information to 
the study. Thus, array-CGH should limit its application to cases with over 50% of 
tumoral cells, as lower proportions may yield a normal genomic profile 
corresponding to the normal cells.76 Third, the production variability among the 
different arrays printed on each laboratory, including the few commercially 
available BAC microarrays. Fourth, these arrays can analyze paraffin-embedded 
tissues, but it largely depends on the DNA quality and integrity isolated from fixed 
cells. Despite these difficulties, whole-genome BAC arrays of ∼1 Mb resolution 
(including 3,000 to 4,000 probes) have been succesfully applied to search for 
genomic changes in many cancer types, allowing an accurate description and 
mapping of areas of genomic amplification and deletion.14,120,136,166-168 These 
alterations can be easily confirmed and visualized in the tumoral cells by 
complementary fluorescence in situ hybridization (FISH) using the same BACs 
as probes.169  
 
Array-CGH devices can be also applied to scan tumor genomes in other species, 
predominantly in laboratory mice,112,170 dogs,171 and Drosophila.172  
 
More recently, tiling resolution human DNA microarrays whith over 32,000 
overlapping BAC clones covering the entire human genome have been 
developed, allowing the identification of minute DNA alterations in tumors not 
previously detected.109,173 However, the presence of such amount of BAC clones 
that cannot be individually verified, and the inclusion of only one BAC per array 
(instead of the 3 to 5 BACs spotted on the 1-Mb BAC arrays) have limited the 
application of these initial arrays.  
 
One advantage of SNP-CGH arrays is that they only use a test (tumoral) DNA 
that is hybridized on the chip, without needing any normal DNA as a control. 
Results of one particular sample are generally “normalized” with respect to 
available data obtained from the study of a pool of normal DNAs; however, to 
increase sensitivity and avoid false positive results, the analysis of tumoral and 
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normal DNAs from each individual in two different arrays is usually 
recommended.174-176 Important limitations of this technology include the poor 
quality results obtained from the analysis of DNAs extracted from paraffin-
embedded tissues and the limitation for the detection of areas of UPD in biopsies 
with more than 50% of non-tumoral cells.  
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8. INTEGRATIVE ONCOGENOMICS: CORRELATION OF GENOMIC 
ABERRATIONS AND GENE EXPRESSION DATA  
  
We describe step by step our recommended sequence of algorithms and 
statistical tests to integrate expression data with copy number data. 
 
1. Derive gene expression levels and raw copy number data. 
The data from the expression and copy number cel files must be pre-processed 
to remove noise and make the arrays comparable between them.  
For gene expression data RMA, GCRMA177,178, dChip or other methods can be 
used. The authors recommend the use of RMA, since it has became the “de 
facto” standard to obtain the expression levels of a gene. 
To derive the raw copy number there are several methods such as CNAT, 
CNAG,179 dChip, and Aroma.affymetrix.180 There are marginal differences 
between them. The most accurate seems to be Aroma.affymetrix. In this case the 
user has to be confident using R programming language. CNAT, CNAG and 
dChip provide convenient user interfaces that Aroma does not. 
There are other packages for the R programming language (SNPChip). The main 
disadvantage that occurs in these packages –and not in Aroma.affymetrix– is 
that all the information of the cel files must be stored in memory limiting the 
number of arrays to be analyzed to a few tens – depending on the type of array. 
There are some special information files related with Affymetrix chips called cdf 
(chip definition files). These files provide the information on how to group each 
single probe into a set of probes. We recommend using the cdf provided by the 
Brainarray Website instead of the Affymetrix default files.181 This website updates 
the information of these files frequently, improving the results of the analysis. On 
the other hand, these definition files have the following advantage: a set of 
probes correspond to a single gene –in the case of Affymetrix a gene can be 
represented by several set of probes making it difficult to know the correct one. 
 
2. Segmentation of the raw copy number data 
Copy number alterations occur in segments of the genome –a whole 
chromosome, an arm of a chromosome or a part of it. This fact can be used to 
extract the parts –segments- of the genome that have the same copy number. 
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The procedure to get these parts from the raw copy number data is called 
segmentation. 
There are various algorithms to perform the segmentation. Three of the most 
widely spread used are CBS (circular binary segmentation),176 HMM (hidden 
markov models) and CGHSeq.182 CNAT, CNAG and dChip provide HMM 
segmentation whereas Aroma uses CBS segmentation. CHGSeq must be used 
under the Matlab platform. 
A major drawback of HMM is that the number of states –and the corresponding 
copy numbers– have to be established beforehand. If there is contamination of 
normal tissue in a tumour sample, copy number will no longer be an integer 
number, and HMM may fail to discern copy number alterations. CBS and 
CGHSeq does not have this problem: they provide an estimation of the copy 
number for each of the segments.  
 
3. Assign copy number values to the genes 
After the described computations, each SNP have its copy number assigned. 
These data have to be combined to assign to each gene its corresponding copy 
number. The copy number for each gene is the mean of the copy number of the 
segments of the genome where the gene is located. 
Genes in which there are copy number changes have to be paid special attention 
since aberrant splicing forms can occur.  
 
4. Remove effects in expression data that are not related with the 
position in the genome 
Segmentation can be also applied to expression data to locate segments of the 
genome with genes over or under expressed. If applied to expression data, it is 
better to apply CBS or CGHSeq since there are no obvious means to establish 
the states beforehand (as needed by HMM). Another possibility is to apply a filter 
(a moving average across the position in the genome) to the normalized 
expression data. The weights of this filter can follow a Gaussian distribution 
(Gaussian filter). 
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Figure 2. Representation of chromosomes 17 an 18. Top: Percentage of samples with increase 
or decrease in DNA copy number. Floor: Percentage of samples with overexpressed or 
underexpressed genes. In the chromosome 18, a high number of samples (more than a 40%) 
show overexpression of the loci corresponding to the BCL2 gene. 
 
  
 
5. Detection of cytobands whose genes have their copy number or their 
expression significantly modified.  
The authors suggest to perform a hypergeometric test to detect which are the 
cytobands whose genes show a significant variation in copy number (increase or 
decrease). The hypergeometric test has four parameters: N (the total number of 
genes), n (the total number of genes in the cytoband), K (the number of genes 
with copy number up) and k (the number of genes within a cytoband with copy 
number up). This test provides a pvalue that describes whether the number of 
genes with copy number up is especially large, i.e. statistically significant, for a 
particular cytoband. This test can be performed against all the cytobands in the 
genome (about 300) and for all the samples within the study. The same 
procedure can be applied to gene expression to detect cytobands cytobands 
whose genes show a significant variation in their expression.  
 
6. Global analysis of copy number and expression changes within a 
study. A simple procedure to describe which are the locus in the genome that 
show variation within a study is to show the percentage of samples that have 
variation in the copy number (up or down) and coherent variation of gene 
expression, i.e. percentage of samples that shows increase in the copy number 
and up regulation (Figure 2). This figure shows the results a study with 29 
lymphoma cell lines. Two chromosomes are shown (Chr. 17 and 18), each with 
two graphics. The upper plot shows the percentage of samples with copy number 
up and down. The lower plot shows the percentage of samples with copy number 
and expression up (or down). It can be seen, for example, that 17q21.31 shows 
several genes that have increased both their copy number and their expression. 
18q21.31 shows also an increase in copy number and expression. The gene 
BCL2 is located in this region. 
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